Prices via Intrinio. Supplier and customer ties are extracted from SEC filings and carry the sentence they came from. Not investment advice.
Prices via Intrinio. Supplier and customer ties are extracted from SEC filings and carry the sentence they came from. Not investment advice.
IDEAYA Biosciences, Inc.
Price, suppliers and customers from SEC filings, institutional ownership and the next report.
Nasdaq · Pharmaceutical Preparations
Prev close 37.63 · gapped above the open, then crossed back over prior close. High/low 38.29 at 4:00 am ET, 37.23 at 10:45 am ET.
Sources
sec edgar · verbatim disclosureEach tie, with the sentence that disclosed it. Open a row for the wording and the filing it came from.
“In August 2025, we entered into an exclusive license agreement with Les Laboratoires Servier (Servier), for the development and commercialization of darovasertib outside of the United States.”
FILING10-K0001193125-26-054533cik 0001676725
“We are conducting a Phase 1/2 clinical trial pursuant to a Clinical Study Collaboration and Supply Agreement (CSCSA) with Gilead to evaluate IDE397 in combination with Trodelvy (sacituzumab govitecan-hziy), Gilead's Trop-2 directed TOP1 ADC, in patients with MTAP-deletion urothelial cancer (UC), and non-small cell lung cancer (NSCLC).”
FILING10-K0001193125-26-054533cik 0001676725
“Dosing of the first patient with IDE034 will trigger a $5.0 million milestone payment to Biocytogen, pursuant to our Option and License Agreement.”
FILING10-K0001193125-26-054533cik 0001676725
“We are evaluating darovasertib in combination with crizotinib, Pfizer's oral c-MET inhibitor, in a potentially registration-enabling, Phase 2/3 trial (OptimUM-02) for human leukocyte antigen-A*02:01 negative (HLA*A2(-)), patients with first line (1L) mUM.”
FILING10-K0001193125-26-054533cik 0001676725
“IDE849 is a potential first-in-class, DLL3 TOP1 ADC being evaluated by our partner, Hengrui Pharma, in a multi-site, open label Phase 1 clinical trial in China in patients with small-cell lung cancer (SCLC) and neuroendocrine carcinomas (NEC).”
FILING10-K0001193125-26-054533cik 0001676725
Watchlist prices, news filtered to it, and its next report on your desk.
IDEAYA Biosciences, Inc. has 3 disclosed suppliers and 2 disclosed customers. Each one is named in an SEC filing, either IDEAYA Biosciences, Inc.’s own annual report or the counterparty’s, and carries the sentence that discloses it.
IDYA (IDEAYA Biosciences, Inc.) has 3 disclosed suppliers and 2 disclosed customers, strongest disclosure first.
Suppliers:
Customers:
Select a tie for the filing sentence that discloses it; select again to open the company. Lines are disclosed suppliers and customers, coloured by industry; the closer to the centre, the more the filings disclose. A dot is green or red by today’s move. Extended: satellites hang off single companies, not bundled sectors.
Largest move on the map today: PFE −0.67%, in healthcare.